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In the present project, we extend the previous studies of Origanum majorana by 
evaluating the anti-cancer potential of this plant extract on proliferation of colon 
cancer. Toward this, we first evaluated the effect of the plant extract on the 
proliferation and DNA damage, in vitro, of the human colon cancer HT-29 cell line. 
We also determine the mechanism by which Origanum majorana induced cell death 
by this extract using biochemical approach. Our results revealed that O. majorana 
inhibited the growth of HT-29 cells by effecting the cells viability. Further work 
showed the ability of the extract to cause DNA damage, cell cycle arrest and 
apoptotic death through activation of caspase 8 and 3 pathways. In conclusion our 
data recommend Origanum majorana is an effective inhibitor for colon cancer 
progression and more investigation has to explore the Origanum majorana extract in 
vivo.  
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Title and Abstract (in Arabic) 
 
 الملخص
 على خاليا سرطان القولون ماجورانانبتة األوريجانوتأثير مستخلص 
  
بحٍذ  (،O.majorana) اَانذساساث سابمت اجشٌج عهى َبخت األوسٌجاَىياجىس ا  ايخذادهزِ األطشوحت حعبخش
. نمذ (colon cancer) ًَى سشطاٌ انمىنىٌ هىفً هزِ انُبخت ع نذاساست إنى حمٍٍى يضاداث انسشطاٌحهذف هزِ ا
ش عهى فً انًخخب DNA damage)) حًج دساست حأرٍش هزا انًسخخهص انُباحً عهى ًَى وحهف انحًض انُىوي
خذاو باسخ انسشطاٍَت هزِ انُبخت عهى لخم انخالٌا َساٌ. كًا حى ححذٌذ كٍفٍت آنٍت عًمنإلخالٌا سشطاٌ انمىنىٌ 
ٌ َبخت أنذساست خائج هزِ اوأظهشث َ (.(biochemical approaches طشق انكًٍٍاء انحٍىٌت
خالل انخأرٍش عهى حٍىٌت انخالٌا  ًَى سشطاٌ انمىنىٌ يٍ ربطج( (O. majorana ساَااألوسٌجاَىياجى
((cells viability ٌماف دوسة إو  انُىوي،حالف انحًض إإضافت إنى رنك أظهشث هزِ انُبت انمذسة عهى و
عٍ طشٌك (  (programed cell death- apoptosisانًبشيج و لخم انخالٌا (cell cycle arrest) انخهٍت
 زبظكً اَاهزِ انُخائج حىصً بُبخت األوسٌجاَىياجىس فئٌ انخخاووفً . (Caspase8 &3)٣و  ٨حفعٍم كاسبٍز 
 بحادًزٌذ يٍ األانوسٍخى إجشاء (colon cancer progression) ىنىٌنما وًَى سشطاٌرش عهى حمذو ؤي
 .انحً انكائٍ انُباحً عهى جسىالسخكشاف حأرٍش هزا انًسخخهص 
 
، حهف انحًض انُىوي، حٍىٌت انخالٌا، سشطاٌ انمىنىٌ، َبخت األوسٌجاَىياجىساَا مفاهيم البحث الرئيسية:
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Chapter 1: Introduction 
 
1.1 Cancer 
Cancer is a multifactorial disease that is characterized by an abnormal growth of cells 
and the migration of those cells from their original site to other sites in the body 
(Alberts et al., 2002). Cancer is a major health problem worldwide.  It is considered 
to be the second leading cause of death in high-income countries (cardiovascular 
diseases is the first) and the third leading cause of death in middle- and low-income 
countries (after cardiovascular diseases and infectious and parasitic diseases) 
(American Cancer Society, 2012b). Statistics from the International Agency for 
Research on Cancer (IARC), indicated that 14.1 million cases were diagnosed with 
cancer in 2012 worldwide. While total cancer deaths reached 8.2 million in the same 
year (International Agency for Research on Cancer, 2012). Terrifyingly the global 
burden is expected to grow to 21.7 million new cancer cases and 13 million cancer 
deaths by 2030 (American Cancer Society, 2012a). In UAE 1729 cancer incidences 
were reported in 2012 (Health Autority, 2012). 
There are over 100 types of cancer that have been classified based on their tissue 
origin. Carcinomas are types of cancer that originate from epithelial cells. Cancer 
that affects the cells of the lymph system is known as lymphoma. Sarcomas are 
cancers that occur in mesoderm such as bone and muscles, while adenocarcinomas 
are cancers that derived from glandular tissue such as breast (Alberts et al., 2002). 
Cancer can be caused by several factors that can be classified into internal and 
external factors. Internal factors include genomic instability and mutations that could 






hand, external factors include environmental causes such as ultraviolet, diet and 
smoking (American Cancer Society, 2012b). 
Basic hallmarks of cancer were described in a considerable scientific work by 
Hanahan and Weinberg. These hallmarks include abnormal induction of proliferative 
signals, over expression of oncogene, cells survive rather than performing apoptosis, 
unlimited cell division, angiogenesis (formation of new blood vessels) and tumor 
metastasis (migration of the cells from their original site) (Hanahan & Weinberg, 
2011). Additional hallmarks are indicated in Figure 1.  
Tumors can be classified according to their migration status into benign or 
malignant. Benigns are primary tumors consist of abnormal cells that accumulate in a 
dormant state which originate in a specific tissue and do not migrate to different 
locations (Adams et al., 2010; Teiten, Gaascht et al., 2010). However, malignant 
tumors are known to migrate from their primary site, through the extracellular matrix 
(ECM), blood, lymph and the endothelium of the affected tissues to develop 



























1.2 Colorectal Cancer 
1.2.1 Functions of the Colon 
Colon also called the large intestine is an organ of the digestive system that function 
to absorb water and store the waste-products of digestion until the body is ready to 
empty them out (Elias, 2012). Under normal condition, the colonic epithelium is 
renewed constantly by crypt proliferative cells which migrate upward along the 
crypt-villi axis as they terminally differentiate (Lipkin, 1973). The average time for 
these cells to proliferate is one day, and around 25% of the colonic epithelium is 
rejuvenated every day. Moreover, the crypt epithelial cells of the entire colon and 
rectum are replaced every three to four days (Lipkin, 1973). 
 
1.2.2 Understanding Colorectal Cancer 
Colorectal cancer is one of the most common cancers worldwide. According to the 
American Cancer Society, in 2012 colorectal cancer found to be the third most 
common cancer in men and the second in women. Approximately, 1.4 million cases 
of colorectal cancer occurred in 2012 worldwide. Around 693,900 deaths from 
colorectal cancer occurred in 2012 worldwide, which accounts for 8% of all cancer 
deaths (American Cancer Society, 2012b). As for UAE, colorectal cancer is 
considered to be the third common cancer, and the fourth leading cause of death 
among other cancers (Health Autority, 2012). 
Colorectal cancer induced from multiple genetic and epigenetic changes leading to 
the transformation of colon epithelial cells into invasive adenocarcinomas (Ng & Yu, 






non-polyposis syndromes. Polyposis syndrome is the familial adenomatous polyposis 
(FAP), which is associated with mutated gene or loss of FAP (also called the 
adenomatous polyposis coli (APC) gene (Grady, 2003). Non-polyposis colorectal 
cancer (HNPCC) syndrome is hereditary, which is associated with germ-line 
mutations in DNA mismatch repair genes (Labianca et al., 2010). 
 
1.3 Apoptosis 
1.3.1 Programmed Cell Death or Apoptosis  
There are several types of cell death such as autophagy, necrosis and apoptosis. 
Apoptosis is a highly regulated process of cell death that is characterized by 
morphological changes such as cell shrinkage, membrane blabbing, chromatin 
condensation, and nuclear fragmentation (Kerr et al., 1972). The balance between 
cell growth, differentiation and cell death for maintenance of cellular homeostasis 
(Rupnarain, Dlamini, Naicker, & Bhoola, 2004). 
Apoptosis is an effective therapeutic mechanism in cancer therapy by designing 
drugs that induce apoptosis in tumor cells without any disturbance to the healthy 
tissues (Micheau & Tschopp, 2003; Zouet al., 1999). Cells may be induced to 
undergo apoptosis by extracellular signals “death factors” which is considered as an 
extrinsic pathway. While the other pathway induced by internal physical or 








1.3.1.1 The Extrinsic Pathway 
External signals are part of the normal control which insure that individual cells 
behave for the good of the organism as a whole, through surviving when they are 
needed and killing themselves when they are not. Several extracellular signals 
stimulate apoptosis, while other inhibit it (Alberts et al., 2002; Pecorino, 2012). 
Some extracellular signals stimulate apoptosis such as death factors. Examples of 
death factors are Fas ligand or tumor necrosis factor (TNF) and both received 
through transmembrane death receptors such as Fas receptor or TNF receptor 
respectively. Fas ligand is bound to the plasma membrane of neighboring cells, while 
TNF is a soluble factor. Once ligand bind to the death receptor, the receptor 
undergoes conformational changes in-order to transmit the signal into the cell. These 
conformational changes lead to the exposure of the death domains which are located 
on the cytoplasmic tail of the receptors and enable intracellular adaptor proteins to 
bind through their death domains (Micheau & Tschopp, 2003).  Example of 
intracellular adaptor proteins are Fas-associated death domain protein (FADD) and 
TNF receptor-associated death domain protein (TRADD) (Backus et al., 2002). 
These adaptor proteins found to transduce the death signal from the receptor to 
caspases. The adapters recruit procaspase-8 molecules through death effector 
domains (DEDs). Once all the procaspases-8 molecules close to each other, they 
become activated by self-cleavage. Caspase-8 is well-known to link between the 
receptor and the apoptotic proteases for that reason it’s called as an initiator caspase 
for the extrinsic cascade. All of them together, the death ligands, receptors, adaptors, 
and initiators caspases are called death inducing signaling complex (DISC). Caspase 






the executioner caspases (caspase 3, 6 and 7).   As a result, cleavage of specific target 
proteins occur which lead to apoptosis (Pecorino, 2012). 
 
1.3.1.2 The Intrinsic Pathway 
Cells can activate their apoptosis program internally, usually in response to injury or 
stresses (e.g., DNA damage or lack of oxygen or nutrients). The intracellular 
activation of apoptotic pathway occurs through the intrinsic pathway of apoptosis, 
which depends on the release of cytochrome c from the mitochondria to the cellular 
cytosol. Once it is released into the cytosol it binds to procaspases activation adaptor 
protein called apoptotic protease activating factor-1 (Apaf1) (Adrain & Martin, 
2001). That causes the oligomerization of Apaf1 into a wheel like heptamer called 
apoptosome. Consequently, the apoptosome recruits initiator procaspase proteins 
(Procaspase-9) that will be activated to from caspase-9 (cleaved form). The activated 
caspase-9 which will activate downstream executioner procaspases to induce 


















1.4 Mitotic Cell Cycle 
Cells reproduce via duplicating their contents and dividing into two. This cycle of 
division and duplication known as a cell cycle. These processes are defined into two 
major phases which are S phase (DNA synthesis and chromosome duplication) and 
M phase (chromosome segregation and cell division). The M phase includes two 
major events; nuclear division (mitosis) and cell division (cytokinesis) (Alberts et al., 
2002).  
Most cell cycles contain additional phases that are called gap phases. These gap 
phases provide additional time for chromosomes duplication and segregation that are 
needed for cell growth generally. Additionally, these gaps serve as transition 
regulators in the cell cycle progression.  The first gap phase, G1, found before S 
phase, while G2 occurs before M phase (Morgan, 2007).    
The central components of the cell-cycle control system that include check points 
which regulate the transition from one phase to another are family of enzymes called 
cyclin-dependent kinases (Cdks). Cdks belong to serine/threonine protein kinases 
which are activated at specific points during cell cycle. They get activated via 
binding to regulatory proteins called cyclins. Different cyclin-Cdks complexes are 
present at specific stage in the cell cycle and are important to regulate irreversible 
phase transition. Any defects in cell cycle regulation can result in developmental 
abnormalities and cancerous growth (Keaton, 2007).  
The p16 (from INK family) and p21 (from Cip/Kip family) are proteins inhibitors 
that involved in regulating cyclin-Cdks activity. The p16 family includes p16, p15, 






found to interact with cyclin-Cdks complexes by blocking the ATP-binding site, 
therefore disabling their kinase activity which leads to cell cycle arrest (Pecorino, 
2012). 
 
1.5 Treatments of Cancer 
There are many types of cancer treatments, and these types are depending on the type 
of cancer and how advanced it is. These treatments include surgery, chemotherapy, 
radiation therapy, hormonal therapy or combined therapy. However, these kinds of 
therapies known to have different side-effects. Hence, identification and 
development of new chemotherapeutic agents from plants “Phytochemicals” have 
gained significant recognition in the field of cancer therapy and become a major area 
of experimental cancer research (Lin,et al., 2002). Recently, scientists all over the 
world are concentrating on the herbal medicines to fight against cancer. By 
understanding the complex synergistic interaction of various constituents of 
anticancer herbs, new novel herbal anticancer agents can be discovered and designed 
to attack the cancerous cells without affecting normal cells of the body 
(Pratheeshkumar, 2012). 
 
1.5.1   Phytochemicals 
Plants have been shown to be an excellent source of new drugs, including anticancer 
agents. There are convincing evidences from experimental studies that highlighted 
the importance of naturally occurring compounds derived from plants in reducing the 






development of molecular and biochemical isolation and purification techniques, 
many anticancer agents derived from plants have been identified and developed. 
During the last 20 years, more than 25% of drugs that are used were directly derived 
from plants, while the other 25% were chemically altered natural products (Cragg & 
Newman, 2000) . Different examples of anticancer drugs derived from plants are 
currently in use in clinical fields. These include vinca alkaloids vinblastine and 
vincristine that were isolated from Catharanroseus, terpene paclitaxel from 
Taxusbrevifolia Nutt., and the DNA topoisomerase I inhibitor camptothecin from 
Camptothecaacuminate (Kaczirek et al., 2004). Moreover, there are other types of 
promising bioactive compounds derived from plants, are currently in clinical trials or 
preclinical trials or undergoing further investigation. Examples include flavopiridol, 
roscovitine, combretastatin A-4, betulinic acid and silvestrol. Different studies 
mentioned the importance of consuming fruits and vegetables, as a source of 
phytochemicals, in reducing the incidence of cancer. These includes vitamins 
(carotenoids) and food polyphenols, flavonoids, phytoalexins, phenolic acids indoles 
and sulfur rich compounds (Vági et al., 2005). The advantage of using such 
compounds for cancer treatment is their non-toxic nature. An ideal phytochemical is 
one that has anti-tumor properties with minimal or no toxicity and has a defined 
mechanism of action. 
 
1.5.1.1  Origanum majorana 
One of these plant used for their availability of phytochemicals is Origanum 
majorana which belongs Lamiaceae family. Commonly known as marjoram. A large 






has a long history of both culinary and medicinal use. O. majorana is used as a home 
cure for chest infection, stomach disorders, cough, nervous disorders, sore throat, 
rheumatic pain, cardiovascular diseases, and skin care (Al-Harbi, 2011; Vági et al., 
2005). Several studies used marjoram species both in vitro and in vivo approaches. 
These studies indicated that O. majorana is very rich in phenolic compounds. The 
high phenolics content in Origanum has a capacity to scavenge free radicals and is 
shown to be associated with strong antioxidant activity (Miron, Plaza, Bahrim, 
Ibáñez, & Herrero, 2011). O. marjorama was shown to contain phenolic terpenoids 
(thymol and carvacrol), tannins, flavonoids (diosmetin, luteolin, and apigenin), 
phenolic glycosides (arbutin, methyl arbutin, vitexin, orientin, and thymonin), 
hydroquinone, and triterpenoids (ursolic acid and oleanolic acid) (Tsimogiannis, 
Stavrakaki, & Oreopoulou, 2006). In addition, O. majorana has been reported to 
exhibit a significant anti-microbial activity (Leeja & Thoppil, 2007). Several studies 
have also revealed that ethanolic, aqueous extracts and essential oil of O. majorana 
could protect against kidney and liver damage and genotoxicity induced by lead 
acetate (I. El-Ashmawy, 2014; I. M. El-Ashmawy, El-Nahas, & Salama, 2005; I. M. 
El-Ashmawy, Saleh, & Salama, 2007). O. majorana has also been shown to inhibit 
platelet adhesion aggregation and secretion (Yazdanparast & Shahriyary, 2008). A 
study by Al Harbi shows that extract of O. majorana reduced the side effects of 
cyclophosphamide, an established anticancer drug, without altering its cytotoxicity 







1.5.1.2  Origanum majorana and Cancer  
In previous studies, it has been shown that Origanum majorana extract (OME) was 
able to inhibit the proliferation of the MDA-MB-231 breast cancer cell lines in time 
and concentration-dependent manner. By using deferent concentrations, OME elicits 
different effects on the MDA-MB 231 cells (I. M. El-Ashmawy et al., 2007). Low 
concentration induced an accumulation of apoptotic –resistant population of cells 
arrested in mitosis and overexpressing the cyclin-dependent kinase inhibitor, p21 and 
the inhibitor of apoptosis, survivin.  On the other hand, higher concentration of OME 
triggered a massive apoptosis through the extrinsic pathway, including the activation 
of tumor necrosis factor-α (TNF-α), caspase 8, caspase 3, and cleavage of PARP, 
downregulation of survivn and depletion of the mutant p53 in MDA-MB-231 cell (Al 
Dhaheri, Eid, et al., 2013a). Moreover, it was demonstrated that non-cytotoxic 
concentrations of O. majorana significantly inhibited the migration and invasion of 
the MDA-MB-231 cells as shown by wound-healing and matrigel invasion assay. 
Also it has been showed that O. majorana induced homotypic aggregation of MDA-
MB-231 associated with an upregulation of E-cadherin protein and promoter activity. 
Furthermore, O. majorana decreased the adhesion of MDA-MB-231 to HUVECs 
and inhibited transendothelial migration of MDA-MB-231 through TNF-α-activated 
HUVECs. Gelatin zymography assay showed that O. majorana suppressed the 
activities of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9). ELISA, RT-
PCR and Western blot results revealed that O. majorana decreased the expression of 
MMP-2, MMP-9, urokinase plasminogen activator receptor (uPAR), ICAM-1 and 
VEGF. Further investigation revealed that O. majorana suppressed the 
phosphorylation of IκB, down-regulated the nuclear level of NFκB and reduced 






showed that Origanum majorana promoted tumor growth inhibition and blocked 
metastasis in vivo using chick embryo tumor growth assay (Al Dhaheri, Attoub, et 







Chapter 2: Materials and Methods 
 
2.1 Preparation of O. majorana Extracts 
Dried leaves of the plant (5.0 gm) were ground to powder by using mortar and pestle. 
Then, the fine samples were embedded in 100ml of 70% ethanol and kept in dark at 
4ºC. This combination was refrigerated without stirring. After for 72 hours, the 
mixture was filtered and evaporated at room temperature. The green residue was 
vacuumed for 2–3 hours. Finally, the extract mass was recorded. 
 
2.2 Cell Culture 
Human cancer cell lines HT-29, were maintained in DMEM cell growth medium 
completed with 10% fetal bovine serum and 100U/ml penicillin/streptomycin and L-
Glutamine. Cells were maintained in a humidified incubator at 37°C in a 5% 
CO2atmosphere. 
 
2.3 Cell Viability 
Cancer cells were seeded at a density of 6,000 cells / well in 96-well plates. After 24 
h, cells were treated for various time (24, 48 or 72h) with increasing concentrations 
of the O. majorana extract (0, 75, 150, 300, 450, 600µg/ml). Experiments were 
carried out in triplicate and repeated 5 times. Control cells were treated with vehicle 
(ethanol). The effect of drugs on cell viability was determined using cytotoxicity kit 






using microplate reader. The data presented as proportional viability (%) by 
comparing the treated group with the untreated cells, the viability of which is 
assumed to be 100%. 
 
2.4 Western Blot 
Western blot technique was used to detect the expression levels of several proteins 
involved in cell death, DNA damage as well as cell cycle regulators. Proteins were 
extracted from treated and untreated cells. Using RIPA lysis buffer (25mM Tris•HCl 
pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS). The lysates 
were centrifuged at 13000 rpm for 30 min. and the supernatants were collected and 
protein concentration measurements were performed. Aliquots of the lysates were 
separated via SDS–PAGE, and then it was transferred onto a nitrocellulose 
membrane. After blocking with 5% non-fat dried milk containing phosphate- 
buffered saline (PBS) and 0.1% Tween-20 for one hour, the membranes were 
incubated overnight with primary antibodies, followed by an additional incubation 
with secondary antibodies. A variety of human antibodies were used at different 
dilutions according to the manufacturer instruction as primary antibodies, and 
secondary antibodies such as horseradish peroxidase-conjugated goat anti-rabbit or 









2.5 Statistical Analysis 
 Results were expressed as means ± S.E.M. of the number of experiments. A 
Student’s t-test for paired or unpaired values was performed and a p value of <0.01 











Chapter 3: Results 
 
 
3.1 O. Majorana Extract Inhibits the Viability of the HT-29 Colon Cancer Cells 
We started our study by testing the effect of Origanum majorana extract (OME) on 
colon cancer cells by measuring the viability of these cells using different 
concentrations of the extract (0, 75, 150, 300, 450 and 600 µg/mL) on the cultured 
HT-29 colon cancer cell line for different incubation periods (Figure 3). Our results 
which have been compared to a vehicle containing control have shown that the 
exposure of the HT-29 to OME decreased cellular viability in a concentration- and a 
time-dependent manner. In the control culture of HT-29 cells which was treated with 
ethanol only, cancer cells proliferated in a constant rate.  The IC50 (producing half-
maximal inhibition) was approximately 450 µg/mL at 24 h,250 µg/mL at 48 h, and 
300 µg/mL at 72h treatment. Obviously, there is a decline in the number of the viable 

















Figure 3: Effect of O. majorana on cell viability of colon cancer HT-29. Cell 








3.2 O. majorana Extract Induces Morphological Changes in HT-29 Colon 
Cancer Cells. 
The observation of the OME-treated HT-29 cells based on light microscopy also 
showed that the number of treated cancer cells decreased when the concentration of 
drug increased. Furthermore, under light microscopy observation of HT-29 cells 
treated with various concentrations of 150, 300, 450 and 600 µg/mL OME. Cells 
underwent morphological changes which occurred after 48 hours of treatment such 






















Figure 4: Morphological changes in HT-29 cells treated with OME.  Morphological 
changes observed in the treated HT-29 cells after 48 hours. Images taken at 40x and 
400x magnifications. Cells were examined under EVOS XL Core Cell Imaging 









3.3 Origanum majorana extract induces cell death (apoptosis) in HT-29 colon 
Cancer Cells through caspase 3activation 
Caspase 3 is considered as one of the most important executioner caspases in 
apoptosis which causes cell death. As shown in Figure 5, after exposure of HT-29 
cells to OME, our experiment revealed that there is a basic level of caspase 3 in the 
control cells. However, there was an increase in the activecaspase 3 level in the 
treated cells especially at concentration of (300 µg/ml 450 µg/ml and 600ug/ml) 








Figure 5 : An increase in the level of caspase 3 in cells treated with OME treated 
cells. Cells were treated with or without increasing concentrations of OME for 48 hr. 









3.4 Significant induction of apoptosis by O.majorana extract in HT-29 cells. 
To further confirmation the induction of apoptosis using OME on HT-29 cell, we 
decided to investigate PARP expression in the treated cell. Because PARP is 
considered as an apoptosis marker, cells were treated with different doses for 48h. As 
shown in figure 6, a high accumulation of cleaved PARP was detected in 









Figure 6: Induction of apoptosis by O.majorana extract in HT-29 cells. Cells were 
treated for 48 hr. with different concentrations of the OME extract and proteins were 








3.5 Origanum majorana Extract Activates the Extrinsic Pathway for Apoptosis 
via down regulation of Pro-caspase 8. 
After we explored the activity of caspase 3 induced by OME, we decided to 
determine the cell death pathway if it’s extrinsic or intrinsic by examining the 
activity of the initiator caspase. Therefore, we investigated the activity of pro-caspase 
8, the inactive form, in different OME concentrations on HT-29. Interestingly, we 
found that after 48h of treatment, pro-caspase 8 level decreases in a concentration 
dependent manner (Figure 7). As a result, that lead to the increase of active form of 
caspase 8 (cleaved form). Therefore, we concluded that OME induce apoptosis 







Figure 7: A decrease in the expression of pro-caspase 8 in cells treated with OME 
treated cells. Cells were treated with or without increasing concentrations of OME. 









3.6 Origanum majorana Leads to Upregulation of p21 in treated HT-29 cells 
By western blot analysis, we observed an up-regulation in the expression of p21 in 
the treated cells. Actually, the cell cycle (in normal cases) occurs in a checked matter 
in the presence of regulator proteins, CDK and cyclin. CDK protein becomes active 
when it binds to cyclin. In cancer cells, there is uncontrolled cell division. Hence, the 
role of CDK inhibitor protein P21 plays a critical role in inducing cell cycle arrest. 
P21 binds to CDK and stops its activity by inhibiting cyclin binding. Abbas and 
Dutta showed that p21 might has a role in promoting apoptosis via both p53-
independent and p53-dependent mechanisms below certain cellular stresses and 
responses. However, the exact role of how p21 promotes apoptosis is not yet clear. 
Nonetheless could depend on both p53-independent and p53-dependent up-
regulation of the proapoptotic protein BAX, effects on DNA repair or activation of 
members of the TNF family of death receptors (Gartel, 2005). Different studies 
showed a pro-apoptotic role for p21, it was revealed only that apoptosis coexisted 
with induction of p21 without defining whether p21 is needed for the induction of 
apoptosis. Therefore, a careful analysis is required to explore the exact role of p21 
under these conditions.Upon applying different concentrations of OME, low 
concentration of OME (150 µg/mL of OME) did not show any induction of p21 
compared to higher concentrations.  Upregulation of p21 protein started with higher 
dose of OME (Figure 8). Based on that, we can demonstrate that p21 expression 








Figure 8: Expression levels of p21 in O.majorana-treated HT-29 cells. Cells were 
treated with or without increasing concentrations of OME. Western blot analysis was 










3.7 Detection of γH2AX, a Marker of DNA fragmentation, in Treated HT-29 
Cells with O. majorana Extract 
Finally, we wanted to investigate whether OME caused DNA damage in HT-29 cells. 
HT-29 cells were treated with either ethanol (control) or various concentrations of 
OME (150, 300, 450 and 600 mg/mL). After 48 h, the level of γH2AX was measured 
to indicate the DNA damage. A Western blotting analysis revealed a concentration- 
dependent increase in the levels of γH2AX in response to OME treatment (Figure 9), 










Figure 9:  O. majorana extract induces a dose-dependent activation of γH2AX, a 
marker of DNA double-strands breaks in HT-29 colon cancer cells. Western blot 
analysis of γH2AX in HT-29 cells exposed for 48h with the indicated concentrations 










Chapter 4: Discussion 
 
Nowadays, finding a balance in cell proliferation expected to be a master key in 
homeostatic maintenance by inhibiting uncontrolled cells proliferation. Through 
arresting the cell cycle and induction of apoptosis in progressed cancer cells. An 
increasing number of evidences focused on the importance of phytochemicals and 
their effect in the metastasis of different cancers including colon cancer. At this 
study, we have illustrated that the Origanum majorana extract inhibited the 
proliferation of the colon cancer cell line HT-29. We have investigated a cell death 
mechanism which inhibit the cell cancer growth.  
Firstly, we studied cell viability of treated cells with O. majorana extract. We have 
shown a significant cytotoxic effect of the OME on the HT-29 which was in time and 
dose manners.  Morphological changes were detected on the treated cells which 
revealed that colon cancer cells went through cell death. Consequently, we tried to 
investigate the mechanism that caused the cell death. 
Our data based on experimental molecular studies demonstrated that O. Majorana 
extract induced a cell cycle arrest linked with a high expression of P21. OME 
triggered the apoptotic cell death by activation of caspase 8 as we showed that by 
detecting the level of caspase 8 as a marker of extrinsic pathway. Furthermore, we 
revealed a DNA damage by a high expression of γH2AX.  
Apoptosis is a very important cell death process that kill cancer cells in two different 
pathways, either extrinsic pathway or intrinsic pathway which can be characterized 
by the caspases that are stimulated and activated in the cells. In general, the extrinsic 






Fas (Pecorino, 2012). The death receptors ligation with their ligands activate caspase 
8 and this event consequently activate caspase 3 which lead to PARP cleavage and 
ultimately apoptosis (Gupta, 2003). In our study, we found that O.majorana extract 
inhibited the colon cancer cells growth by activation of caspase 8. In our 
experiments, the level of procaspase 8 was very high at the control then it started to 
decrease with higher concentrations of OME, that means procaspase-8 has been 
cleaved into its active form which is caspase 8. 
Actually, caspase 3 is activated by both pathways of apoptosis, extrinsic and intrinsic 
and it leads to an effective destruction of the cell followed by a death. Apoptotic cell 
death is caspase mediated through the cleavage of multiple proteins crucial in 
cellular functioning (Fischer, Jänicke, & Schulze-Osthoff, 2003). For further 
conformation of apoptosis, cleavage of PARP should be detected (Kaufmann, 
Desnoyers, Ottaviano, Davidson, & Poirier, 1993; Tewari et al., 1995). PARP is 
known to have an essentialrole in DNA damage detection and repair. Therefore cells 
with damaged DNA have amplified PARP (Herceg & Wang, 1999; Lemaire, 
Andréau, Souvannavong, & Adam, 1998). 
We wanted to highlight the cleavage of PARP in our treated cells. PARP inhibition is 
found to be related to many cellular alterations. However, PARP fragments detected 
by western blot is recognized as biomarkers for specific protease activity in 
programed cell death. As shown in our results, PARP cleavage was increase 
dramatically with dose dependent manner.   
On the other hand, DNA damage is estimated as one of the molecular signals 
associated with cell cycle arrest and apoptosis. So, we measured the level of γH2AX 






concentrations in OME treated cells.  Our result demonstrates that OME caused a 
double stranded DNA damage in a concentration dependent manner.  
Alongside with DNA damage and cell cycle arrest, we liked to explore if DNA 
damage is leading to a cycle arrest. p21 plays a major role in inhibiting CDK which 
leads to a growth arrest. Therefore, we studied the expression of the CDK inhibitor, 
p21, in treated HT-29. Interestingly, an increase expression of P21 was detected in 
the treated cells. The cycle cell arrest or in other word the growth arrest is correlated 
with apoptosis in most cases of cell death (Sambucetti et al., 1999).  
 In previous study, a team of the lab have demonstrated that the Origanum majorana 
extract inhibited the proliferation of the mutant p53 triple negative breast cancer 
(TNBC) cell line, MDA-MB-231. They induced a cell cycle arrest at G2/M phase and 
this cell cycle arrest correlates with an overexpression of the CDK inhibitor p21. Growth 
arrest is successfully induced by OME in our present study with a need of more exploring in 
investigating the expression of CDK inhibitor.  By the previous study data, At high 
concentrations of OME, apoptosis was induced via activating the cell death extrinsic 
pathway which was mediated by the activation of TNF-α and activation of caspase 8. They 
have also shown that apoptosis is also mediated by an increase in DNA damage, revealed by 
the expression of γH2AX, (Al Dhaheri, Eid, et al., 2013b). We have shown the same results 
of the OME effect in activating the extrinsic apoptotic pathway and how this extract 
induces DNA damage in human colon cancer cells HT-29 cell line. The similarity in 
our present study results and the previous study data on the effect of OME on 
different human cancer cells confirms the efficiency of the extract in inhibition the 
cancer cells growth and more study and careful experiments are needed to be done in 







In conclusion, our study demonstrated that Origanum majorana extract effects HT-
29 in concentration-dependent manner. At high concentrations, OME induced DNA 
damage indicated by the upregulation of γH2AX and this DNA damage leads to 
growth arrest. Moreover, DNA damage also induced an extrinsic apoptosis pathway, 
mediated by activation of procaspase 8 which is connected to PARP cleavage 
through caspase3. The suggested apoptosis pathway of OME on HT-29 is shown in 



















Figure 10: The proposed model shows the effect of Origanum majorana on HT-29 










Chapter 5: Conclusion 
 
In conclusion, we have illustrated that the Origanum majorana plant extract effect 
the colon cancer cell line HT-29 successfully by inducing DNA damage and growth 
arrest. Furthermore, our data have shown the potential of this treatment in activating 
apoptosis in the colon cancer cells. In future, we are looking for further laboratory 
research and investigations to study the effect of OME on the HT-29 cells migration 
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